NCT00107952View on ClinicalTrials.gov

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

PHASE3CompletedINTERVENTIONAL
Enrollment

761

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Bacterial Pneumonia
Interventions
DRUG

Telavancin

Telavancin 10 mg/kg/day IV for up to 21 days.

DRUG

Vancomycin

Vancomycin 1 Gm IV q 12 hrs for up to 21 days

Trial Locations (1)

01199

Baystate Medical Center, Springfield

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY